NASDAQ:ALNYAlnylam Pharmaceuticals Stock Price, Forecast & News

Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALNY stock has increased by 36.2% and is now trading at $138.82. View which stocks have been most impacted by Coronavirus.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($1.62) earnings per share for the quarter, topping analysts' consensus estimates of ($1.89) by $0.27. The biopharmaceutical company had revenue of $71.94 million for the quarter, compared to analyst estimates of $90.45 million. Alnylam Pharmaceuticals had a negative return on equity of 57.63% and a negative net margin of 310.01%. The company's revenue for the quarter was up 173.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.42) earnings per share. View Alnylam Pharmaceuticals' earnings history.

18 brokers have issued 12-month price objectives for Alnylam Pharmaceuticals' shares. Their forecasts range from $74.00 to $202.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $151.28 in the next twelve months. This suggests a possible upside of 9.0% from the stock's current price. View analysts' price targets for Alnylam Pharmaceuticals.

News headlines about ALNY stock have been trending very negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutAlnylam Pharmaceuticals.

Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), Opko Health (OPK), AbbVie (ABBV) and Vertex Pharmaceuticals (VRTX).

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Alnylam Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (10.70%), BlackRock Inc. (7.58%), Baillie Gifford & Co. (7.44%), State Street Corp (2.60%), Morgan Stanley (1.21%) and Morgan Stanley (1.21%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet. View institutional ownership trends for Alnylam Pharmaceuticals.

ALNY stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Maverick Capital Ltd., Rockefeller Capital Management L.P., Morgan Stanley, Morgan Stanley, Federated Hermes Inc., Pictet Asset Management Ltd., and Quantitative Investment Management LLC. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet. View insider buying and selling activity for Alnylam Pharmaceuticals.

ALNY stock was purchased by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , BlackRock Inc., Janus Henderson Group PLC, Sumitomo Mitsui Trust Holdings Inc., Duquesne Family Office LLC, First Trust Advisors LP, Baillie Gifford & Co., and Capital World Investors. View insider buying and selling activity for Alnylam Pharmaceuticals.

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALNY stock can currently be purchased for approximately $138.82.

Alnylam Pharmaceuticals has a market capitalization of $15.94 billion and generates $219.75 million in revenue each year. The biopharmaceutical company earns $-886,120,000.00 in net income (profit) each year or ($8.11) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,323 workers across the globe.

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]